Levodopa neurotoxicity: experimental studies versus clinical relevance

Neurology
P Jenner, M F Brin

Abstract

Levodopa therapy remains the major form of treatment for the symptoms of Parkinson's disease (PD). However, there has been a suspicion that its use may hasten the progression of nigral cell degeneration. This concept is based on the ability of levodopa to generate reactive oxygen species and the apparent involvement of oxidative stress as a component of the degenerative process that occurs in PD. Indeed, in vitro autoxidation of levodopa causes oxidative stress, leading to neuronal destruction by necrosis or apoptosis. However, its chronic administration to normal rats or primates has not been associated with clear evidence for destruction of the nigrostriatal pathway. In contrast, in situations in which the nigrostriatal tract is already damaged, there is some evidence to suggest that levodopa treatment can produce further cell destruction associated with oxidative processes. However, levodopa does not appear to be toxic to the development of fetal nigral neurons or to the survival of fetal cell transplants. There is no clinical evidence to suggest that levodopa has adverse effects on dopamine cells in normal humans or on the viability of remaining dopaminergic cells in patients with PD. However, it is only now that specific c...Continue Reading

Citations

Sep 17, 2003·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Fei CaoE-tang Tong
May 21, 2009·Journal of Inherited Metabolic Disease·Wang-Tso LeeKai-Yuan Tzen
Jul 5, 2003·Neuropharmacology·Carla PardiniGiovanni U Corsini
Nov 14, 2002·Neurotoxicology·Maria E ReveronGary W Miller
Jul 30, 2003·Neurobiology of Aging·Ippolita Cantuti-CastelvetriJames A Joseph
Sep 10, 2002·Parkinsonism & Related Disorders·Christian PiflOleh Hornykiewicz
Jun 28, 2003·Neurotoxicity Research·Emilia Mabel GattoFederico E Micheli
Mar 27, 2002·Biological & Pharmaceutical Bulletin·Yoshihisa KitamuraTakashi Taniguchi
Mar 8, 2005·Drug Metabolism Reviews·Shufeng ZhouYu-Zong Chen
Dec 13, 2002·Journal of Neuroscience Research·Aleph A Corona-MoralesLimei Zhang
Dec 7, 2010·Neuropharmacology·Brigitte SpinnewynPierre-Etienne Chabrier
Nov 26, 2009·Neurochemistry International·Anupom Borah, Kochupurackal P Mohanakumar
Jan 30, 2007·Progress in Neurobiology·Neha SinghYahya E Choonara
Jul 5, 2011·Progress in Neurobiology·Janusz LipskiNicola B Mercuri
May 1, 2002·Expert Review of Neurotherapeutics·Gurutz J Linazasoro
Dec 24, 2013·Neuroscience·N NevalainenI Strömberg
Jul 9, 2016·Progress in Neurobiology·Philippe De DeurwaerdèreMark J Millan
Feb 19, 2002·The Annals of Pharmacotherapy·Edyta J FrackiewiczNeal R Cutler
Jan 28, 2005·Neurochemical Research·Wei-Guo LiuSheng-Di Chen
Nov 20, 2016·Human Brain Mapping·Wang-Tso LeeSteven Shinn-Forng Peng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Related Papers

The New England Journal of Medicine
J M Feldman, H E Lebovitz
The New England Journal of Medicine
W L Dawson
Movement Disorders : Official Journal of the Movement Disorder Society
Erwan BézardJ A Obeso
© 2022 Meta ULC. All rights reserved